Combination therapy for acute myocardial infarction: Glycoprotein IIb/IIIa inhibitors plus thrombolysis

被引：9

作者：

Cannon, CP

机构：

[1] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Boston, MA USA

来源：

CLINICAL CARDIOLOGY | 1999年 / 22卷 / 08期

关键词：

thrombolysis; fibrinolysis; glycoprotein IIb/IIIa; acute coronary syndrome; combination;

D O I：

10.1002/clc.4960221607

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Although thrombolytic therapy has been a major advance in the treatment of acute ST-segment elevation myocardial infarction (MI), new thrombolytic agents have been unable to improve early reperfusion. Because aspirin has been shown to be a very effective adjunctive agent in patients with acute MI, it has been hypothesized that the use of platelet glycoprotein (GP) IIb/IIIa receptor inhibitors combined with thrombolytic agents would lead to more effective platelet inhibition and improved angiographic and clinical efficacy. Emerging experimental and clinical data, including the Thrombolysis in Myocardial Infarction (TIMI)-14 trial, suggest that combining GP IIb/IIIa receptor inhibition with reduced-dose thrombolytic therapy improves early infarct-related artery patency without increasing bleeding risk. Thus, given the strong clinical and physiologic rationale, clinical investigation in patients with acute ST-segment elevation MI is currently focused on combining GP IIb/IIIa receptor inhibitors with reduced-dose fibrinolytic agents in acute MI.

引用

页码：37 / 43

页数：7

共 57 条

[41]

Simoons ML, 1997, LANCET, V349, P1429

[42]

Tcheng JE, 1997, LANCET, V349, P1422

[43] ASPIRIN, HEPARIN, OR BOTH TO TREAT ACUTE UNSTABLE ANGINA [J].

THEROUX, P ;

OUIMET, H ;

MCCANS, J ;

LATOUR, JG ;

JOLY, P ;

LEVY, G ;

PELLETIER, E ;

JUNEAU, M ;

STASIAK, J ;

DEGUISE, P ;

PELLETIER, GB ;

RINZLER, D ;

WATERS, DD .

NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (17) :1105-1111

[44]

TOPOL E, 1994, CIRCULATION, V90, P1631

[45]

Topol E, 1998, NEW ENGL J MED, V339, P436

[46] Myocardial reperfusion therapy - Emerging platelet preeminence [J].

Topol, EJ .

CIRCULATION, 1998, 97 (02) :211-218

[47] Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade [J].

Topol, EJ ;

Lincoff, AM ;

Califf, RM ;

Tcheng, JE ;

Kleiman, NS ;

Adelman, AG ;

Burton, JR ;

Talley, JD ;

Ivanhoe, RJ ;

Ducas, C ;

Cheung, PK ;

Schick, U ;

Badard, D ;

Kramer, J ;

Leary, J ;

Snyder, H ;

Wilson, R ;

Dearen, M ;

Caramori, P ;

Webber, S ;

Taylor, J ;

Ferrando, T ;

Cohen, E ;

Balleza, L ;

Rouse, C ;

Hogg, N ;

Kelly, T ;

Alston, S ;

Webb, J ;

Buller, E ;

Ricci, DR ;

Mockman, S ;

Tanguay, JF ;

Poitras, AM ;

Timis, G ;

Davey, D ;

Coleman, P ;

Herrold-Runge, P ;

O'Neill, BJ ;

Foshey, K ;

Fitzgerald, N ;

Almond, D ;

Kostuk, W ;

White, J ;

Oskalns, R ;

Gottlieb, R ;

Koren, P ;

Palazzo, D ;

Azrin, M ;

Barry, MB .

LANCET, 1998, 352 (9122) :87-92

[48] Platelet GPIIb-IIIa blockers [J].

Topol, EJ ;

Byzova, TV ;

Plow, EF .

LANCET, 1999, 353 (9148) :227-231

[49] Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta(3) blockade with percutaneous coronary intervention [J].

Topol, EJ ;

Ferguson, JJ ;

Weisman, HF ;

Tcheng, JE ;

Ellis, SG ;

Kleiman, NS ;

Ivanhoe, RJ ;

Wang, AL ;

Miller, DP ;

Anderson, KM ;

Califf, RM .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 278 (06) :479-484

[50]

Topol EJ, 1997, NEW ENGL J MED, V336, P1689

← 1 2 3 4 5 6 →